Navigation Links
Anticancer Drugs Targeting the ErbB (EGFr/HEr2) Pathway Alone Generated Global Sales of Nearly $5 Billion in the First Nine Months of 2007
Date:11/27/2007

Currently, Over 370 Agents are in Active Clinical Development, Addressing

Over 190 Targets

LAKE FOREST, Calif., Nov. 27 /PRNewswire/ -- Six ErbB (EGFr/HEr2)-pathway inhibitors, marketed for the treatment of several major solid tumor indications, generated global sales of $4,964.4 million in the first 9 months of 2007, almost surpassing the $5,160 million total revenues of these agents in 2006.

Despite this unprecedented market success and the acceptance of targeted therapies in oncology practice, many challenges remain unfulfilled. One key problem of currently approved agents is the relatively marginal benefits they provide; median progression-free survival (PFS) and overall survival (OS) are extended only by a few months. However, aggressive efforts to overcome current limitations are providing unique opportunities in this field.

Currently, all targeted therapeutics, both approved and novel are under evaluation almost exclusively in combination with approved cytotoxic agents. Because cytotoxics remain the treatment mainstay for adjuvant, neoadjuvant and advanced/metastatic disease, opportunities still exist for the development of more effective, less toxic alternatives.

Targeted therapeutics are also under investigation in combination with each other, in efforts to simultaneously inhibit additional or compensating pathways, or to maximize effectiveness against a single target by combining drugs acting by different mechanisms, e.g., receptor tyrosine kinase (RTK) inhibitors and monoclonal antibodies (MAb), against the same target. Also, multitargeted inhibitors are in development against different targets in the same or different pathways hypothesized to act in concert in malignancy.

The commercial success of the ErbB inhibitors and other targeted anticancer agents has stimulated R&D in this field. More than 370 drugs have entered clinical trials, with many having already reached phase II (n=183) or phase III (n=43) stages of development. In addition hundreds of agents are in preclinical development. Their mechanisms of action are wide ranging, targeting some of the more than 1,000 different molecular markers implicated in malignancy.

Molecularly targeted agents in development are ushering in the age of personalized medicine. There is pressing need for better diagnostic, theragnostic, prognostic, pharmacogenomic and disease monitoring methodologies for patient selection and optimized treatment.

The source, mechanisms of action, and preclinical and clinical status, including interim and final trial results, of all of these agents are described in detail in New Medicine's Oncology KnowledgeBASE (nm/OK). By interrogating nm/OK users may:

-- Identify novel agents addressing either a single target or multiple

pathways/targets and review in detail their preclinical and clinical

status

-- Locate targeted agents in clinical trials in combination with specific

approved cytotoxic agents or classes of such drugs, i.e. platinum-based

agents, taxanes, etc.

-- Obtain comprehensive, cited data on over 1,000 targets that may be

applicable as diagnostic, theragnostic, prognostic, pharmacogenomic,

disease monitoring and/or therapeutic targets in cancer

-- Obtain interim and final results of combination trials of approved

anticancer agents, by cancer indication, target, clinical development

status, etc.

-- Obtain detailed records of anticancer targets by 100 different cancer

indications, and many subtypes such as non-small cell lung cancer

(nsclc), triple receptor-negative breast cancer, glioblastoma

multiforme (GBM), etc.

-- View detailed records of drugs in development for several hundred

highly specific clinical indications, i.e. advanced or metastatic

disease, adjuvant or neoadjuvant treatment, first line or second line

treatment

-- Obtain detailed preclinical and/or clinical pipelines of over 1,000

developers of anticancer agents, including detailed profiles of the

companies and their affiliates

-- Identify licensing opportunities

-- Assess global market opportunities based on revenues of approved drugs

and the epidemiology of specific cancer indications

-- Create proprietary 'saved searches' to monitor developments in a

pre-selected group of agents chosen by specific shared parameters,

i.e., targets, delivery systems, mechanism of action, cancer

indication, clinical indication, stage of development, etc.

Contact us for an on line demonstration of nm/OK.

Contact: Katie Siafaca

Tel: (949) 830-0448;

Fax: (949) 830-0887

E-mail: info@newmedinc.com

http://www.newmedinc.com

http://nmok.net

http://nmok.net/oksite/samprecords.html


'/>"/>
SOURCE New Medicine's Oncology KnowledgeBASE
Copyright©2007 PR Newswire.
All rights reserved

Related medicine news :

1. New review suggests caution on drugs to raise good cholesterol
2. Can cancer drugs combine forces?
3. Study provides hope that some transplant patients could live free of antirejection drugs
4. Study provides hope that some transplant patients could live free of anti-rejection drugs
5. RA Drugs Linked to Slight Skin Cancer Risk
6. Report on patients access to cancer drugs uses flawed methods to reached flawed conclusions
7. Rock N Roll: Sex, Drugs and an Early Exit
8. Australian-led international study shows blood pressure drugs cut death rate in type 2 diabetes
9. Study suggests brain tumors need treatment with multiple targeted drugs
10. Consumer Reports Analysis: Drugs for Nerve Pain, Fibromyalgia Effective, But Not Always Best
11. Are Bargaining Groups Hired by Independent Drugstores Causing Payment Delays to Pharmacies?
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/24/2017)... ... February 24, 2017 , ... Healthcare Associates of McKinney announced today ... building at 8080 State Highway 121, Suite 210, McKinney, Texas 75070. It is ... 121. , As the practice has grown, the need for more space has been ...
(Date:2/24/2017)... ... February 24, 2017 , ... The California State ... convening academic faculty engaged in or interested in palliative care education and research. The ... be held in North County San Diego on Sept. 28 and 29, 2017, on ...
(Date:2/24/2017)... ... February 24, 2017 , ... Indiana Fiber Network (IFN) ... company later this year. Dyer started as the Chairman of the Management Committee ... establishment of the corporation including the recruitment of investor/owners and development of the business ...
(Date:2/24/2017)... ... February 24, 2017 , ... ... Senior International Elite division on February 12th. Ms. Esparza qualified into this ... elite qualifier competition held in Las Vegas, Nevada. Frida is one of approximately ...
(Date:2/23/2017)... MA (PRWEB) , ... February 23, 2017 , ... ... and Department of Justice jointly issued a letter to withdraw previous ... accordance with their gender identity. The guidance issued in May 2016 by the ...
Breaking Medicine News(10 mins):
(Date:2/24/2017)... 2017 ITL Limited, ( ASX: ITD ... erfreut, für das zum 31. Dezember 2016 endende ... Ergebnisse vorlegen zu können. Eine vollständige Präsentation „Ergebnisse ... finden Sie hier . Glanzpunkte ... (Dez. 2015: 1,04 Millionen USD; +104 %) Gewinn ...
(Date:2/24/2017)... 23, 2017 Non-alcoholic steatohepataitis (NASH) ... various drugs being developed for the treatment ... drugs that are in various phases of ... focuses on novel pharmacologic drugs & regenerative ... therapies, recombinant proteins and RNA-based therapeutics, but ...
(Date:2/24/2017)... Research and Markets has announced the addition ... 2016" report to their offering. ... The latest research Urinary Incontinence Drugs Price ... in the global Urinary Incontinence market. The research answers the ... drugs marketed for Urinary Incontinence and their clinical attributes? How are ...
Breaking Medicine Technology: